Company Encyclopedia
View More
name
AB&B BIO-TECH-B
02627.HK
Ab&B Bio-Tech CO., LTD. JS researchs, develops, manufactures, and sells vaccines and biological preparations that provide active immunity against diseases. The company offers various vaccines, such as human rabies vaccine, pneumococcal vaccine, zoster vaccine, respiratory syncytial virus vaccine, mpox vaccine, varicella vaccine, and tetanus vaccine. The company was founded in 2015 and is based in Taizhou, China.
1.267 T
02627.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    AB&B BIO-TECH-B applies for full circulation of H shares

    According to the Zhitong Finance APP, AB&B BIO-TECH-B announced that on October 15, 2025, the company has submitted an application to the China Securities Regulatory Commission for the conversion of 81.662 million unlisted shares into H shares and for the listing of such shares on the Stock Exchange of Hong Kong

    Zhitong·
    HK
    02627
    -0.93%
    Zhitong·
    HK
    02627
    -0.93%

    Hong Kong stock movement: AB&B BIO-TECH-B rose 11.26%

    AB&B BIO-TECH-B rose 11.26%; WuXi AppTec-B plummeted 46.27%, with a transaction volume of HKD 3.858 billion; Tongyuan Kang Pharmaceutical-B surged 22.21%, with a transaction volume of HKD 2.841 billion; MIRXES-B increased by 5.05%, with a transaction volume of HKD 1.231 billion; BeiGene fell 1.45%, with a market value of HKD 303.7 billion

    HK Stock Movers Tracker·
    HK
    02627
    -0.93%
    HK Stock Movers Tracker·
    HK
    02627
    -0.93%

    Understanding the Market | AB&B BIO-TECH-B rose over 8% as its quadrivalent influenza virus subunit vaccine was selected for the preliminary review list of commercial insurance, significantly highlighting its market scarcity

    AB&B BIO-TECH-B's stock price rose by more than 8%, with an increase of 7.49% as of the time of publication, trading at HKD 51.25, with a transaction volume of HKD 18.463 million. The company's board of directors announced that its quadrivalent influenza virus subunit vaccine for the 6-35 month age group has been approved by the National Medical Products Administration, becoming China's first quadrivalent influenza vaccine for the entire population at full dosage. This vaccine has undergone significant upgrades based on traditional split vaccines, offering advantages such as high purity and low risk of adverse reactions, and has been included in the preliminary review list for commercial insurance, indicating significant market scarcity

    Zhitong·
    HK
    02627
    -0.93%
    Zhitong·
    HK
    02627
    -0.93%

    China's first quadrivalent subunit influenza vaccine for all populations has been approved, and AB&B BIO-TECH-B is about to commercialize it on a large scale

    AB&B BIO-TECH-B's quadrivalent influenza subunit vaccine has been approved by the National Medical Products Administration of China, marking an important breakthrough in its commercialization process. The vaccine is now applicable to individuals aged 6 months and older, becoming China's first quadrivalent influenza vaccine for the entire population, and is expected to fill a market gap. The vaccination rate for influenza vaccines has long been low in China, resulting in significant market demand

    Zhitong·
    HK
    02627
    -0.93%
    Zhitong·
    HK
    02627
    -0.93%

    AB&B BIO-TECH-B: The application for the marketing of the quadrivalent influenza virus subunit vaccine has been approved by the National Medical Products Administration

    AB&B BIO-TECH-B announced that its quadrivalent influenza virus subunit vaccine for the population aged 6 to 35 months has been approved for market launch by the National Medical Products Administration of China. This vaccine is China's first quadrivalent influenza virus subunit vaccine for the entire population and all dosage levels, offering comprehensive protection, high-purity antigens, and a low risk of adverse reactions. The company focuses on the research and commercialization of innovative vaccines, aiming to replace traditional and imported vaccines in the Chinese market

    Zhitong·
    HK
    02627
    -0.93%
    Zhitong·
    HK
    02627
    -0.93%
    Posts
    View More
    © 2025 Longbridge｜Disclaimer